Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc. > Forcing Bioasis to Answer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(132)
•••
Comment by emmitfitzhumeon Jan 16, 2023 9:47pm
111 Views
Post# 35226974

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Forcing Bioasis to Answer

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Forcing Bioasis to AnswerPOF

Just for perspective, a 780 million dollar private placement done at our prior valuation or 13 million would dilute us down to about 1.6%, that’s the percentage shareholders will have in any future success of xb3 in this new structure.  Can we not call that crippling dilution? 

Could there have been no other options which would respect current shareholders, potentially at the cost of less lining of the banker’s pockets?

Let that sink in, and please correct my math, tell me where I am wrong, I’m open to criticism, critique etc., I never did have any gumption for math or finance.   

I would like to hear more about the fairness report conducted by Evans and Evans, what exactly would be considered an unfair deal in terms of dilution for stakeholders?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities